GNBT just in waiting mode. Only down 0.005. When the market was down over 700 GNBT held fine.

30-60 days until up listing...… TICK TOCK TICK TOCK

Market hit HARD and GNBT stable.

Investors know what they have here.

All nonsense. LMAO~!

False. That is why OxyContin reformulated brought up many many many times Bayou.
And it WAS Purdue that made the miscalculation, not Elite. Purdue had something very similar and had to scrap it because it flat out FAILED. They Jason Blewitt. then went to the very cheap easier to abuse OxyContin.
They only WISH they had Elite's patents and formulation(s).LOL~!

And you may want to check up on that revisionist history about Atul Mehta.
Great formulator, lousy at running the company, that is why he was voted out of the company he founded.
And another thing you failed to mention about Atul Mehta that I won't even go into because it was a VERY positive thing, for both him and Elite.

Your turn.... LOL~!

State of Arizona files suit against the Sackler family (Purdue Pharmaceuticals).


https://news.azpm.org/s/68799-arizona-files-suit-against-family-behind-oxycontin/


This suit is asking for $billions$.
But but but I thought the OxyContin formulation was the answer to the opioid crisis. That it was better than Elite's ADF. A big fat NO on both counts. It is the main ingredient for the current opioid crisis. Sacklers know it and so does Purdue Pharmaceuticals.

Don't fret though.... there is always Mundipharma to keep the Sacklers going. What a scam!

And to add insult to injury Purdue has a patented formulation for those who are addicted to opioids like OxyContin. They make $money$ both ways. LMMFAO~! Talk about a paradox. Wow.

SunGen not your typical garage pharmaceutical. As I have told others on another board I know someone that worked at SunGen in New Jersey before SunGen moved to Florida. He stayed in NJ, did not want to move. Now he works for the company I work for.

From what he told me SunGen is a very good company to work for. They treat their employees well. They are on their way to the big leagues. Good that Elite partnered with them. ANDAs #1 through #5, then we shall see what transpires after that.

I will say one thing about CBD topicals for arthritic pain, soreness, and chronic joint pain. It works. Just a little dab (a tiny amount) goes a long way.

Because it is not regulated yet, there are no chemical profiles on it yet, and there are no impurity profiles on these various CBD topicals like other pharmaceutical drugs, user beware.

FDA will more than likely step in to regulate requiring active and impurity
profiles on topicals out there. So far though these types of requirements
do not exist.

It is good stuff though. Takes the pain right away.

N2K, and rrr2003; I give a great deal of credit to NH for his persistence
in pursuit of making Elite a viable pharmaceutical. If it were anyone else
they may have take n a different approach sticking solely with the ADF. As you have pointed out a couple of times N2K, his diversification of the drug portfolio is really what may end up saving Elite's bacon.

Patience is the real key for serious investors right now. When it all plays out we will see who was right and who was dead wrong.

Now is the time to add to ones holdings. Just sit back and wait it out.

docj, Joe can't seem to do anything right and needs advice as to what to do. Didn't you know that? Joe knows less about what's going on at the company then those who haven't even heard the CC. Amazing eh?
Just too funny.... cannot make this stuff up.

You can listen to it right now. It is on their homepage right now.

Transcript...…. LOL~!

Treat your competition as you would mushrooms. Keep them in the dark.
Also, do you realize how much time, effort, and money would be wasted on giving the blow by blow?

One invested their money, now time to wait it out. Hopefully one does not mortgage the farm, but even if one did that is their decision.

The time to plunk some serious cash down on this play is after the application to the FDA for the IND and when the FDA approves the IND.
Or, if things get that far wait for clinicals to start then put some serious $$$ down a month or two in.

Brian... seriously? Like comparing a Ferrari (AMGN) to a car still in the shop (PMCB). Really dumb comparison in my opinion.

To put it another way...… IF PharmaCyte gets through this to the point where they get IND clinical trials under way..... and if that trial is successful...
which of the two stocks would you rather own? Better yet, which gives the most bang for the buck potential with the least amount of money invested?

PCMB.

PCMB if successful will be a buyout target. Possibly AMGN.... or another
company if CiaB is proven out.

Post proof including a link about "toxic notes".
Thanks in advance.

There are no "toxic notes". This is all an attempt to shake the tree, let weak hands fold.

Listened to the CC and found nothing of concern. A stronger balance sheet is about the only thing.

The situation presented itself and yet no questions were posed as to "toxic notes". Did not hear anything during the Q & A. Not one peep....
If such concern about "toxic notes" it should have been asked during the CC and Joe could have been put on the spot. Why wasn't Joe put on the spot?

Fiction, that's why...… pure fiction.

I seriously doubt advice is needed. Company seems to be doing all of the right things. Cleaning the books, getting all things ready for up listing.

Yes... let's see what happens. The handle is forming on this cup.

Newguy, it is pay for play right now. I see it every single day of my working life. Total bull crap. About time to go back to the way things used to be done... the right way, not the money way.

Agency is supposed to look out for us, the public at large. Right now they do not. They need to put healthcare and patient safety first. Put companies that are only interested in the money side on notice. Either play or lose the US market and go elsewhere to hawk your stuff.

In some ways this is like legalizing drug cartels. Time it stopped and it needs to be done at the Federal level.

Solar thank you for sharing the Seeking Alpha article. Only thing I wish is that I had bought more GNBT, but I do have enough to make it worth my while.

If only the ex-CFO were there to make sure GNBT management didn't overlook something.... LMAO~!

Maybe Generex management is winging it.
Again... LMMFAO~!

Even with the older ADF technology Elite has a potent ADF technology.
The newer technology will mean a great deal of cost savings to both the manufacturer and the consumer, however, the two bead technology is still in play and still plays a key role in validating Elite's ADF technology if brought to market. One can almost dismiss the fact that the two bead is more expensive because if approved and brought to market it is likely to be the only ADF out there. NH is acutely aware of this.

Moreover, if approved and brought to market it will exponentially increase the buyout price. It is one thing to acquire patents and technology from a company, and quite another to acquire all that goes with the buyout of a company that has its' technology out on the market. A proven and marketed
technology has more value than one that still needs the FDAs' blessing.

Also cost for both the two bead and the newer technology have to be factored into submission tests for the FDA. SequestOx as well as the newer formulation will need money for that testing.

Meanwhile, Elite keeps it going with approvals and launches of ANDAs such as Adderall IR, the antibiotic, and soon to be CNS ER drug.

Cleaning up the books, the loan, is part of getting ready for up listing.
Do not be fooled into thinking this management is on a death spiral. Once on NASDAQ the institutional investors come in and things really start to take shape.

BTW, the loan outstanding had little to do with GNBT ever going death spiral. Outstanding debt is never good, but a this small debt never put the company at risk. Maybe 9 years ago, not now. Clean up the books for up listing.

Getting ready.

And many CEOs as the Chairman of the board are what set the tone for
the company's endeavours. Good post.

docj here is another one for you concerning GNBT.

http://www.stockta.com/cgi-bin/analysis.pl?symb=GNBT&cobrand=&mode=stock

No "death spiral" in that analysis. Fake stockTA? NOT~!
Looks mighty good to me.

Thank you N2K. That was a very good summary.

Long term pattern of GNBT is a cup and handle. Bullish.

A cup and handle price pattern on bar charts resembles a cup and handle where the cup is in the shape of a "U" and the handle has a slight downward drift.
A cup and handle is considered a bullish continuation pattern and is used to identify buying opportunities.
May be as short as 7 weeks and as long as 65 weeks. This one has been going on a long time. Now in the handle phase.

GLTA

Doubling or tripling of revenue is not zero. Your math is off by a lot.

GNBT makes NASDAQ and it is a whole new ballgame. Institutional investors will climb on board. Should make a good run.

Not a very Rosie outlook there for GNBT. Only as a former CFO should know.

Sorry all wrong. Death spiral seems to be a fixation of GNBT and other stocks. Meanwhile buyers coming. No "death spiral" in sight.

My post was not directed at you NASDAQ. Sorry, unintentional.

IRs formulations are not the sole reason prescription opioids are abused.
Elite has the answer to this dilemma.

Put on the back burner until money allows Elite to continue.
Elite focused on CNS drugs. Two bead technology is still in play. Did not hear to the contrary.

IRs will still be in demand. There is no getting away from it. Unless someone comes up with a better ER that gives immediate pain relief to last 12 - 24 hours. As far as is known that mouse trap does not exist yet.
Until then IRs rule for immediate pain relief.

Exactly~! Shaking the tree for weak hands.

If the requirements were such that this company were in a "death spiral" they would not make NASDAQ listing. Let's see if listing goes through before pronouncing a "death spiral". All requirements to make NASDAQ listing are there.

Second thing, (IF) once on NASDAQ institutional investors will jump on this company bigtime. With the incentive of a 1:1 this could get very interesting.... "death spiral"? As John Wayne would say "Not hardly".

122 + 1; 123 total. We are talking long term holders, not just those who ride the price up and dump out.

I was at the 2014 meeting also, remember the red eye guy? From Hawaii?